
Active Stock in News: Bayer/Regeneron Successfully Expand Eylea Label
The HealthCare segment at Bayer (BAYRY) announced that its blockbuster eye treatment, Eylea, was approved for yet another indication in Japan. The drug was approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of myopic choroidal neovascularization (myopic CNV). Eylea’s approval in the myopic CNV indication was based on encouraging results from the phase III MYRROR study. The drug … Continue reading Active Stock in News: Bayer/Regeneron Successfully Expand Eylea Label